The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFusion Antibody Share News (FAB)

Share Price Information for Fusion Antibody (FAB)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 3.45
Bid: 3.30
Ask: 3.50
Change: 0.00 (0.00%)
Spread: 0.20 (6.061%)
Open: 3.40
High: 3.40
Low: 3.40
Prev. Close: 3.40
FAB Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

AIM WINNERS & LOSERS: Beeks Financial Cloud is ahead of expectations

Tue, 06th Feb 2024 10:05

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Tuesday.

----------

AIM - WINNERS

----------

Beeks Financial Cloud Group PLC, up 34% at 145.00 pence, 12-month range 81.42p-155.00p. The cloud computing and connectivity provider says it has won a number of competitive tenders in the first half of financial 2024, and now expects trading in financial 2025 to be "significantly" ahead of previous board expectations. Beeks notes that it has signed a USD2.3 million Proximity Cloud expansion contract, as well as a conditional contract with "one of the largest exchange groups globally." Chief Executive Gordon McArthur says: "We continue to progress with the execution of our 'land and expand' strategy, quickly demonstrating the value of our offerings, as evidenced by the significant Proximity Cloud expansion contract announced this morning and the winning of a third major global exchange customer for our Exchange Cloud offering. We see considerable expansion potential across our customers, as they migrate increasing proportions of their trading infrastructure to the cloud."

----------

Fusion Antibodies PLC, up 16% at 5.50p, 12-month range 3.02p-56.00p. Shares in the contract researcher rise. It receives a follow-on project under a collaborative research and development agreement with an unnamed "US-based biotechnology company". The follow on project is worth USD650,000. CEO Adrian Kinkaid says: "It is always thrilling and satisfying to share in our clients' successes. We are delighted that the programme has been so productive, and we look forward to continuing to work with our client to bring better antibodies to the clinic more rapidly. The collaborative nature of the project, with creative problem solving from both parties over the full length of the programme, makes this a model example of Fusion's Integrated Therapeutic Antibody Service and highlights the strong reputation that Fusion has for delivering high quality therapeutic antibodies."

----------

AIM - LOSERS

----------

PCI-PAL PLC, down 10% at 49.98p, 12-month range 38.25p-66.70p. Shares in the provider of cloud-based secure payment solutions for business communications fall despite a positive trading update. Revenue in the six months to December 31 rises 20% to GBP8.7 million from GBP7.3 million a year before. Annual recurring revenue in the period increases 23% to GBP14.7 million from GBP11.9 million. Looking ahead, CEO James Barham says: "The start of H2 has seen the group maintain new sales momentum and we continue to focus on delivering the group's profitability objectives, enhancing shareholder value, and capitalising on the strategic opportunities for continued growth."

----------

By Sophie Rose, Alliance News senior reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2024 Alliance News Ltd. All Rights Reserved.

More News
25 Feb 2019 11:56

Fusion Antibodies Guides For Revenue "Materially Below" Market Views

LONDON (Alliance News) - Fusion Antibodies PLC on Monday warned that annual revenue will be "materially below current market expectations" due to the uncertain timing of closure of were

Read more
25 Feb 2019 10:43

Fusion Antibodies dives as revenues falter

(Sharecast News) - Fusion Antibodies' shares plummeted on Monday after the company warned of failing revenues due to uncertainty surrounding the timing of "a number of potential substantial orders".

Read more
17 Dec 2018 14:51

Fusion Antibodies launches new 'RAMP' platform

(Sharecast News) - Pharmaceutical contract research organisation Fusion Antibodies launched its new 'Rational Affinity Maturation Platform' (RAMP) at the Antibody Engineering Conference in San Diego last week, it announced on Monday.

Read more
26 Nov 2018 10:39

Fusion Antibodies Interim Loss Widens On Increasing Competition

LONDON (Alliance News) - Fusion Antibodies PLC on Monday said that increasing competition, pricing pressures, and lower order levels have resulted in a substantial fall in revenue and a sharply of

Read more
26 Nov 2018 10:17

Fusion Antibodies sees losses widen throughout 'challenging' first half

(Sharecast News) - Pharmaceutical research outfit Fusion Antibodies saw losses widen sharply throughout the first half of its trading year after revenues more than halved.

Read more
24 Sep 2018 17:03

DIRECTOR DEALINGS: Fusion Antibodies Non-Executive Buys Shares

LONDON (Alliance News) - Fusion Antibodies PLC said Monday Non-Executive Director Timothy Watts bought shares worth GBP10,237 in the life sciences firm in a transaction last Thursday.Watts

Read more
16 Aug 2018 13:40

Fusion Antibodies Posts Solid Revenue Rise But Warns On Current Trade

LONDON (Alliance News) - Fusion Antibodies PLC on Thursday said it has delivered strong annual revenue growth in a year in which it joined the London Stock Exchange's AIM market.The in

Read more
16 Aug 2018 08:10

Fusion Antibodies gets dragged to a loss as non-recurring items skyrocket

(Sharecast News) - Contract researcher Fusion Antibodies saw revenues hit £2.7m in its last trading year but was unable to chalk up a profit.

Read more
16 Aug 2018 08:10

Fusion Antibodies gets dragged to a loss as non-recurring items skyrocket

(Sharecast News) - Contract researcher Fusion Antibodies saw revenues hit £2.7m in its last trading year but was unable to chalk up a profit.

Read more
13 Aug 2018 10:31

WINNERS & LOSERS SUMMARY: Chemring Says Fatal Accident To Hurt Profit

LONDON (Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Monday.----------FTSE 100 - WINNERS----------BAE up 0.8%. a

Read more
13 Aug 2018 10:26

Fusion Antibodies Shares Fall 30% After Profit Warning For New Year

LONDON (Alliance News) - Shares fell in Fusion Antibodies PLC on Monday as it reported that trading in its current financial year to date has been slower than expected, due to increase competition

Read more
13 Aug 2018 08:27

Fusion Antibodies shares tumble following downbeat outlook

(Sharecast News) - Fusion Antibodies shares crashed on Monday morning after the Belfast-based researcher revealed that year-to-date trading had been "slower than anticipated".

Read more
24 May 2018 14:59

Fusion Antibodies Receives Up To GBP213,000 Grant From Invest NI

LONDON (Alliance News) - Fusion Antibodies PLC said Thursday it received additional grants from regional business development agency Invest Northern Ireland of up to GBP213,000.The company

Read more
4 Apr 2018 08:00

Qatar's market manipulation fears fuelled by "abnormal" derivative moves-bank CEO

* Qatar c. bank probing market manipulation during Gulf standoff * Qatar's top bank helping central bank with probe * QNB says has cash

Read more
29 Mar 2018 14:03

MIDEAST STOCKS-Saudi retreats after winning FTSE emerging status, rest of region strong

* Saudi market had surged before FTSE decision * Profit-taking is moderate, little downside seen * Other Gulf bourses may get some relief from fund outflows * blue chips climb

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.